Investigational drug · Phase 3
Avexitide
Also called: exendin 9-39
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Post Bariatric Hypoglycemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
47
Any phase or sponsor naming "Avexitide"
First trial start
2025
Apr 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Avexitide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Post Bariatric Hypoglycemia
Largest trials
Live from ClinicalTrials.gov: studies naming "Avexitide" as an intervention, largest first.
- Cardiovascular Effects of GLP-1 Receptor ActivationPivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT03101930 · 329 participants · Start May 1, 2017 · Primary completion Jun 24, 2021
Drug: Liraglutide; Sitagliptin and 2 more · For: Obesity; PreDiabetes
Sites: Nashville, Tennessee
- The Effects of Bariatric Surgeries on Glucose MetabolismPivotal-lookingRecruiting
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT02823665 · 200 participants (planned) · Start Jul 2015 · Primary completion Aug 2026
Drug: Exendin-(9-39); Atropine · For: Post Bariatric Surgery; Gastric Bypass; Sleeve Gastrectomy and 1 more
Sites: San Antonio, Texas · 2 sites in all
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruiting
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT00992901 · 160 participants (planned) · Start Oct 2009 · Primary completion Aug 2026
Drug: Exendin-(9-39); Atropine and 1 more · For: Post Bariatricsurgery; Hypoglycemia
Sites: San Antonio, Texas · 2 sites in all
- Gastrointestinal Sensorimotor Dysfunctions in Diabetes MellitusPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT02170870 · 104 participants · Start Jun 2014 · Primary completion Nov 17, 2017
Drug: Exendin 9-39; Microlipid and 1 more · For: Dyspepsia; Diabetes Mellitus With Gastrointestinal Symptoms
Sites: Rochester, Minnesota
- Islet Function in Gestational DiabetesRecruiting
Mayo ClinicAcademic, hospital or other
NCT07806695 · 90 participants (planned) · Start Sep 2026 · Primary completion Mar 2030
Drug: Exendin 9-39 · For: Gestational Diabetes Mellitus
Sites: Rochester, Minnesota
- The Effect of rs7903146 Genotype on Islet GLP-1 Production in HumansNot yet recruiting
Mayo ClinicAcademic, hospital or other
NCT06972407 · 80 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2028
Drug: Exendin 9-39 · For: Genetic Predisposition; Type2diabetes
Sites: Rochester, Minnesota
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT01803451 · 80 participants (planned) · Start Nov 2005 · Primary completion Aug 2026
Drug: exendin-(9-39); exendin -(9-39) · For: Post-bariatric Surgery
Sites: San Antonio, Texas · 2 sites in all
Carl T. Hayden VA Medical CenterFederal agency
NCT01181986 · 76 participants · Start Aug 2010 · Primary completion Dec 2012
Drug: Exenatide SC; Exenatide IV and 3 more · For: Type 2 Diabetes Mellitus
Sites: Phoenix, Arizona
- Avexitide for Treatment of Post-Bariatric HypoglycemiaPivotal-lookingActive, not recruiting
Amylyx Pharmaceuticals Inc.Industry
NCT06747468 · 75 participants (planned) · Start Apr 29, 2025 · Primary completion Jul 8, 2026
Drug: Avexitide · For: Post Bariatric Hypoglycemia
Sites: Stanford, California; Aurora, Colorado; Jacksonville, Florida · 21 sites in all
Diabeteszentrum Bad Lauterberg im HarzAcademic, hospital or other
NCT02639130 · 67 participants · Start Feb 2008 · Primary completion Jan 2010
Drug: Exendin [9-39]; Placebo · For: Type 2 Diabetes
Sites: Bad Lauterberg im Harz, Germany
Newest research
PubMed records naming it or its code names, newest first.
- GLP-1 Enhances IL-27 Production in RAW264.7 Macrophages Via Activation of the PI3K/AKT Pathway.
Jiao Y, Dong S, Liu Z, et al. · J Interferon Cytokine Res 2026
- Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study.
Craig C, Tan M, Shamloo T, et al. · Metabolism 2026
- Semaglutide and pioglitazone restore airway mucosal homeostasis by resolving Pseudomonas aeruginosa pyocyanin-induced mucus hypersecretion, ciliostasis, and type 2 airway inflammation.
Wu C, Kulkarni NA, Lew SQ, et al. · Front Immunol 2026
- Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent Signaling.
Pavshintsev VV, Erbaeva AZ, Vatlin AA, et al. · Biomedicines 2026
- Contractile effects of dulaglutide in the human atrium.
Neumann J, Jarikova M, Hofmann B, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Yueju pill exerts rapid antidepressant effects via sequential activation of hippocampal GLP-1 receptor and PACAP signaling in mice.
Xing S, Peng Y, Wang Y, et al. · J Ethnopharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.